Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Metformin-Based Supramolecular Nanoparticle Platforms for Atherosclerosis Therapy

FY 2023-24

Summary
Atherosclerosis begins with cholesterol depositing within the arterial wall. Overtime, the cholesterol filled plaque grows and arteries narrow. In severe cases, the arteries get blocked, leading to heart related issues such as heart attack and stroke. Previously, researchers have tried decreasing plaque sizes by delivering medication to the vessels. However, the medication would degrade before reaching the vessel or end up in the wrong location in the body, causing side effects. Our objective is to safely deliver these tested medications to atherosclerotic plaques, thereby regulating the disease. Nanotechnology is a developing domain of research and drug delivery. Like an envelope does for a letter, a nanoparticle can encapsulate medications, protecting them from degrading in the body. Additionally, like the address on an envelope, a nanoparticle has a molecule on its surface, targeting it to the appropriate organ. Our team will encapsulate GW 3965 & metformin, drugs that reduce atherosclerotic plaque development, in a nanoparticle and deliver them to blocked vessels. We hypothesize that the nanoparticle should both protect the drugs from getting degraded in the body & target the drugs to the blocked vessel, decreasing the likelihood of developing side effects. Notably, we will be optimizing the medical potential of our nanoparticle system by using a dual drug therapy rather than a single drug therapy. We will test the effects of our combination therapy in both a laboratory setting and in mice models. In the long-term, the targeted co-delivery of this drug-particle in humans should heal diseased vessels and thus reverse heart disease development.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
525509
Name
Gahunia Esha K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Metformin-Based Supramolecular Nanoparticle Platforms for Atherosclerosis Therapy
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Atherosclerosis; Biomedical; Cardiovascular Diseases; Cell Biology; Nanotechnology
Abstract
Atherosclerosis begins with cholesterol depositing within the arterial wall. Overtime, the cholesterol filled plaque grows and arteries narrow. In severe cases, the arteries get blocked, leading to heart related issues such as heart attack and stroke. Previously, researchers have tried decreasing plaque sizes by delivering medication to the vessels. However, the medication would degrade before reaching the vessel or end up in the wrong location in the body, causing side effects. Our objective is to safely deliver these tested medications to atherosclerotic plaques, thereby regulating the disease. Nanotechnology is a developing domain of research and drug delivery. Like an envelope does for a letter, a nanoparticle can encapsulate medications, protecting them from degrading in the body. Additionally, like the address on an envelope, a nanoparticle has a molecule on its surface, targeting it to the appropriate organ. Our team will encapsulate GW 3965 & metformin, drugs that reduce atherosclerotic plaque development, in a nanoparticle and deliver them to blocked vessels. We hypothesize that the nanoparticle should both protect the drugs from getting degraded in the body & target the drugs to the blocked vessel, decreasing the likelihood of developing side effects. Notably, we will be optimizing the medical potential of our nanoparticle system by using a dual drug therapy rather than a single drug therapy. We will test the effects of our combination therapy in both a laboratory setting and in mice models. In the long-term, the targeted co-delivery of this drug-particle in humans should heal diseased vessels and thus reverse heart disease development.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gahunia, Esha K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~